Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Study of Givinostat in Chronic Myeloproliferative Neoplasms
NCT01761968Phase 2Active, not recruiting
- Sponsor
- Italfarmaco
- Start
- Mar 2013
- Primary completion
- Dec 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of givinostat in polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by Italfarmaco. Started Mar 2013; status: active, not recruiting.
02
Drugs
givinostat
03
Conditions
polycythemia vera (PV)essential thrombocythemia (ET)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT01761968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01761968.